Comprehensive analysis of SETD1B mutation frequency in lymphoma across multiple studies. (A) Estimated allele frequency in tumor patient samples from MSK DLBCL and MSK FL studies. (B and C) Dot plot representing the (B) SETD1B and (C) KMT2D mRNA expression levels in altered and non-altered DLBCL patient samples (TCGA, Pan Cancer Atlas, Sanchez-Vega et al., 2018). (D) Table representing SIFT scores for SETD1B missense mutations found in TCGA, PanCancer Atlas database (Sanchez-Vega et al., 2018). (E) Oncoprint representation of mutation status of KMT2 family genes in 1,295 samples from published DLBCL sequencing studies. Samples are arranged in columns with genes labeled along rows. Only samples with alterations are shown. (F and G) Pie charts showing the frequency of SETD1B mutations in a cohort of (F) FL and (G) DLBCL patients with wild-type or mutated KMT2D. Patients with KMT2D mutations have a higher likelihood of having mutations in SETD1B in both cohorts. (H) Oncoprint representation of mutation status of SETD1B and TP53 genes in 1,295 samples from published DLBCL sequencing studies (P = 0.55). P values were calculated with two-sided Fisher Exact test.